Severe Trauma
Conditions
Interventions
experimental:Pyridostigmine Bromide
Placebo:Placebo
Sponsors
State Key Laboratory of Trauma, Burns, and Combined Injury, Department 1, Research Institute of Surgery, Daping Hospital, The Third Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Good adherence to patients and their families with informed consents; 2. ICU Inpatients with ages between 18-65; 3. Admitted within 72 hours after injury and be diagnosed as severe trauma; 4. APACHE II >=15 or ISS >=16 points, the expected survival time> 7 days.
Exclusion criteria
Exclusion criteria: 1. History of any of the following: stenocardia, atrioventricular block, bronchial asthma, mechanical intestinal obstruction, Urinary tract infarction, Postoperative atelectasis or pneumonia, Advanced neurological disease; 2. Use of cholinergic, anti-cholinergic, or beta-blocking medications; 3. Current treatment with medications known to interact with pyridostigmine; 4. Known intolerance of oral preparations containing bromides; 5. splenectomy or splenic neurectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of sepsis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Critical Illness score;health related quality of life score;hemodynamic parameters;vagal nerve activity;concentration of pro- and anti-inflammatory cytokines;the levels of plasma catecholamine; | — |
Countries
China
Contacts
Public ContactHuaping Liang
Outcome results
None listed